



Research Article

Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy

Vladimir D. Dergachev¹, Ekaterina E. Yakovleva^{1,2}, Maria A. Brusina¹, Evgeny R. Bychkov¹, Levon B. Piotrovskiy¹, Petr D. Shabanov¹

1 Institute of Experimental Medicine, 12 Acad. Pavlov Str., St. Petersburg 197376 Russia

2 Saint-Petersburg Pediatric Medical University, 2 Litovskaya Str., St. Petersburg 194100 Russia

Corresponding author: Vladimir D. Dergachev (ovd18@bk.ru)

Academic editor: Oleg Gudyrev 🔹 Received 04 November 2022 🔹 Accepted 05 March 2023 🔹 Published 31 March 2023

Citation: Dergachev VD, Yakovleva EE, Brusina MA, Bychkov ER, Piotrovskiy LB, Shabanov PD (2023) Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy. Research Results in Pharmacology 9(1): 41–47. https://doi.org/10.18413/rrpharmacology.9.10006

Abstract

Introduction: To study the antiparkinsonian activity of new ligands of the glutamate NMDA receptor complex – 1,2–substituted imidazole-4,5-dicarboxylic acids – on an experimental model of catalepsy caused by haloperidol intraabdominal injections in rats.

Materials and methods: The experiments were performed on Wistar rats weighing 300-350 g, obtained from the Rappolovo nursery of the Russian Academy of Medical Sciences (Leningrad Region). The animals were kept in standard plastic cages in vivarium conditions with free access to water and food at a temperature of 22 ± 2 °C and in the experiment were divided into several groups (6 animals each). All the experiments were carried out in the autumn-winter period. The animals were kept in accordance with the rules of laboratory practice (GLP), regulatory documents "Sanitary Rules for the Device, Equipment and Maintenance of Vivarium" and the Order of the Ministry of Health and Social Development of the Russian Federation dated 23.08.2010 No. 708n "On Approval of the Rules of Laboratory Practice". Imidazole-dicarboxylic acid derivatives (IEM-2295, IEM-2296) were injected intraperitoneally at doses from 5 mg/kg to 40 mg/kg simultaneously with haloperidol at a dose of 1 mg/kg, after which the duration and severity of catalepsy were evaluated after 30, 60, 120 minutes from 0 to 6 points according to the Morpurgo method.

Results: The severity of catalepsy with the injection of IEM-2295 decreased on average to 3 points, while in the control group it remained at the level of 6 points throughout the observation. However, the severity of catalepsy with the introduction of IEM-2296 decreased to an average of 4 points, but the effect itself lasted longer than with the introduction of IEM-2295. Thus, it was noted that by the 120th minute of observation, the severity of catalepsy in rats receiving the IEM-2295 compound averaged 5 points, whereas in animals receiving IEM-2296 – 3 points.

Discussion: Basing on the results of our work and similar experiments, we can conclude that the studied compounds, which are not channel blockers, have an active effect on dopaminergic neurotransmission, because of which the symptoms of catalepsy that occur when haloperidol is injected to rats were stopped to one degree or another.

Conclusion: The studied substances exhibit antiparkinsonian activity on an experimental haloperidol model of catalepsy in rats and are promising for development as potential therapies for neurodegenerative diseases. Further study of these compounds and other ligands from the NMDA-blocker group in a wider sample on the catalepsy model, as well as on other models of Parkinsonism, is required.

Copyright *Dergachev VD et al.* This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Graphical Abstract



Keywords

NMDA receptor antagonists, haloperidol, dopamine, parkinsonism.

Introduction

Parkinson's disease (PD) is one of the urgent problems of world science and medicine. Along with secondary parkinsonism, PD is the most common neurodegenerative disease in the seniors the progression of which leads to disability (Poewe et al. 2017; Chia et al. 2020). Nowadays due to the increase in life expectancy, the tendency to shift middle age towards the seniors population, the number of patients with Parkinsonism is constantly growing, which increases the urgency of finding effective and safe therapy for this neurological pathology (Draoui et al. 2020).

More than 50 years have passed since the first use of levodopa, but it remains the most effective option for drug therapy. All this time, levodopa-induced complications have been the object of careful study and attempts to find a solution to this problem. The arsenal of medical treatment methods aimed at optimizing the motor control of progressive PD is constantly expanding (Aradi and Hauser 2020). The basis for effective lifelong therapy of PD is an individual approach to the treatment of patients, taking into account the peculiarities of the clinical picture, concomitant diseases and other factors (Fox et al. 2018; Jankovic and Tan 2020; Tarakad 2020). Therapeutic strategies for PD are aimed at a number of symptoms, including impaired

motor functions - bradykinesia, rigidity and tremor, as well as relief of complications of long-term use of levodopa (Kulisevsky et al. 2018).

Pharmacological groups, such as central dopaminomimetics (dopamine receptor agonists, NMDA receptor antagonists), central holinoblockers and drugs that restore dopamine levels (COMT inhibitors, MAO inhibitors, including levodopa drugs), are used as medicines aimed at correcting extrapyramidal disorders in PD (Chou et al. 2018; Aradi and Hauser 2020). Unfortunately, modern research shows that long-term combination therapy, helping to cope with the main manifestations of PD, inevitably leads to side effects, such as drowsiness, hallucinations, dyskinesia, nausea, dizziness, constipation and many others (Li et al. 2017). In this regard, the search for effective antiparkinsonian drugs devoid of the above adverse reactions remains an urgent task of modern neuropharmacology.

NMDA receptors are ion channels containing tetrameric groupings of GluN1 and GluN2 receptor subunits that mediate excitatory neurotransmission in the central nervous system. NMDA receptors containing the GluN2D subunit are most relevant as a target for antiparkinsonian therapy due to their expression in some nuclei of the basal ganglia, which demonstrate abnormal excitation patterns in parkinsonism, in particular in the subthalamic nucleus (Standaert et al. 1994, Bhattacharya et al. 2018). It is proved that glutamate NMDA receptors play a significant role in the development of Parkinsonism, which makes it possible to consider the development of NMDA ligands as one of the priority areas of PD therapy (Haas et al. 2018; Vanle et al. 2018; Groc and Choquet 2020; Vieira et al. 2020).

Excessive activity of NMDA receptors causes a state of excitotoxicity and promotes cell death, which underlies the potential mechanism of neurodegeneration. Activation of synaptic NMDA receptors initiates plasticity and stimulates cell survival. On the contrary, activation of non-synaptic NMDA receptors promotes cell death and thereby contributes to the development of neurodegeneration, which can be stopped by the action of NMDA receptor antagonists selectively blocking their function (Wang and Reddy 2017).

One of such drugs registered in Russia for the treatment of PD is the non-competitive NMDA blocker amantadine, while various NMDA receptor antagonists are undergoing preclinical and clinical trials (Müller et al. 2019). The first results of the study of the aminoadamantane antiparkinsonian activity of (amantadine) in PD were published in 1969. After 50 years, the drug is still available worldwide and is indicated for the treatment of PD, both in the early and late stages. Amantadine has a unique dual (dopaminergic and non-dopaminergic) pharmacodynamic profile, which makes this drug the only representative of the original class of antiparkinsonian drugs. Initially, an assumption was made about the effect of amantadine on the release and/or reuptake of dopamine, subsequently its uncompetitive antagonism to glutamate NMDA receptors was revealed (Schwab 1969; Perez-Lloret and Rascol 2018; Rascol et al. 2020).

In addition, it is believed that another mechanism of antiparkinsonian action of NMDA receptor antagonists is a decrease in dopamine-dependent acetylcholine release in the striatum. An imbalance of inhibitory and excitatory effects on GABAergic neurons under the tonic influence of dopaminergic projections of the substantia nigra, glutamatergic projections of the cortex and cholinergic projections of the striatum leads to increased dopamine-dependent release of acetylcholine in the striatum. Thus, NMDA blockers have an indirect cholinonegative effect, preventing synaptic release of acetylcholine and thus exhibiting antiparkinsonian activity (Iakovleva et al. 2020). This mechanism was studied and described earlier, using a model based on the activation of the cholinergic system (arecolineinduced tremor model) (Dergachev et al. 2021).

It should be remembered at the same time that in pathology, hyperactivation of ionotropic glutamate receptors leads to a sharp increase in transmembrane calcium current into the cell, followed by the release of Ca2+ from intracellular depots, depolarization of the mitochondrial membrane and, as a consequence, a prolonged increase in the amount of Ca²⁺ in the cytoplasm. The high content of Ca²⁺ in neurons triggers neurotoxic processes with activation of proteolytic enzymes and destruction of cellular structures, which eventually leads to increased synthesis of nitric oxide, activation of lipid peroxidation and, consequently, to oxidative stress, impaired synthesis of neurotrophic factors and apoptosis (Szydlowska and Tymianski 2010). It follows from this that glutamate excitotoxicity can not only trigger, but also aggravate the neurodegenerative process in PD (Mironova et al. 2018). In this regard, the safety problems associated with glutamatergic modulation are still relevant and consist in the extremely important role of glutamate and its receptors in the key functions of the central nervous system. That is why the priority direction of the development of compounds from the group of NMDA ligands is the search for means to influence the glutamatergic system by soft, controlled, and safe modulation.

Materials and Methods

Animals

The experiments were performed on Wistar rats weighing 300-350 g, obtained from the Rappolovo nursery of the Russian Academy of Medical Sciences (Leningrad Region). The animals were kept in standard plastic cages in vivarium conditions with free access to water and food at a temperature of 22 ± 2 °C and in the experiment were divided into several groups (6 animals each). All the experiments were carried out in the autumn-winter period. The animals were kept in accordance with the rules of laboratory practice (GLP), regulatory documents "Sanitary Rules for the Device, Equipment and Maintenance of Vivarium" and the Order of the Ministry of Health and Social Development of the Russian Federation dated 23.08.2010 No. 708n "On Approval of the Rules of Laboratory Practice".

The studied compounds: IEM-2295, IEM-2296 – are the derivatives of imidazole-4,5-dicarboxylic acid.

Experimental model

A model of catalepsy caused by haloperidol was chosen as a model for studying antiparkinsonian activity, which consists in stimulating dopaminergic transmission of the studied compounds (Mironov et al. 2012). This model is a proven method of studying extrapyramidal disorders, which is used everywhere (Cieślik et al. 2019; Ramírez-Jarquín et al. 2020; Cárcel and De la Casa 2021).

Parkinsonism caused by the use of neuroleptics is the second most common pathogenetic variant in the world after PD. Haloperidol is a first-generation neuroleptic commonly used for the relief of acute and chronic psychoses, the treatment of behavior disorders, personality changes and other psychopathologies. The mechanism of action of haloperidol is associated with the blockade of dopamine receptors, central alphaadrenoblocking action and disruption of the process of reverse neuronal capture and deposition of adrenaline. Unfortunately, the use of haloperidol is limited by the side effects of the drug, in particular extrapyramidal disorders (Kabra et al. 2020).

Imidazole-dicarboxylic acid derivatives (IEM-2295, IEM-2296) were injected intraperitoneally at doses from 5 mg/kg to 40 mg/kg simultaneously with haloperidol at a dose of 1 mg/kg, after which the duration and severity of catalepsy were evaluated after 30, 60, 120 minutes from 0 to 6 points according to the Morpurgo method (Mironov et al. 2012).

Statistical analysis

Statistical processing of the results was carried out using

MS Excel 2010 and BioStat 2009. The normality of the data distribution was determined by the Shapiro-Wilk criterion. The reliability of the differences in values between the groups was defined using nonparametric criteria: Kruskal-Wallis and Fisher's exact criterion.

Results

It is necessary to accentuate a concentration of 30 mg/kg with the injection of the test substance IEM-2295. Against the background of the injection of the test agent at this dose, there was a significant difference from the control group at 30^{th} min (p=0.002671), 60^{th} min (p=0.028441) and 120^{th} min (p=0.027851) of observation (Figs 1, 2, 3).



Figure 1. Differences in the severity of catalepsy between the control group and the group receiving IEM-2295 at a concentration of 30 mg/kg at the 30^{th} minute of the experiment. (p=0.002671).

Figure 2. Differences in the severity of catalepsy between the control group and the group receiving IEM-2295 at a concentration of 30 mg/kg, at the 60^{th} minute of the experiment. (p=0.028441).

Figure 3. Differences in the severity of catalepsy between the control group and the group receiving IEM2295 at a concentration of 30 mg/kg at the 120^{th} minute of the experiment. (p=0.027851).

It is necessary to accentuate a concentration of 20 mg/kg with the injection of the test substance IEM-2296. Against the background of the injection of the test agent at this dose, there was a significant difference from the control group at 30^{th} min (p=0.020241), 60^{th} min (p=0.045553) and 120^{th} min (p=0.045328) of observation, as evidenced by the data presented in Figures 4, 5 and 6.



Figure 4. Differences in the severity of catalepsy between the control group and the group receiving IEM2296 at a concentration of 20 mg/kg, at the 30^{th} minute of the experiment. (p= 0.020241).



Figure 5. Differences in the severity of catalepsy between the control group and the group receiving IEM2296 at a concentration of 20 mg/kg, at the 60th minute of the experiment. (p= minute 0.045553). (p= 0.045553)

Figure 6. Differences in the severity of catalepsy between the control group and the group receiving IEM2296 at a concentration of 20 mg/kg, at the 120^{th} minute of the experiment. (p= 0.045328).

Discussion

The first NMDA receptor antagonists for the treatment of Parkinson's disease were successfully used lowaffinity channel blockers amantadine and memantine (Danysz et al. 1997). The clinical efficacy of NMDA receptor antagonists is obviously based on several complementary mechanisms: firstly, the close glutamatergic interweaving of dopamine and projections in the brain regions responsible for the initiation of movements and motor activity; secondly, the mutual regulation of presynaptic dopamine release by glutamate receptors and vice versa; and thirdly, there is indisputable evidence of the interaction of these mediator systems at the postsynaptic and systemic levels (Christoffersen and Meltzer 1995).

The deep interrelation of the dopamine and glutamatergic systems is confirmed by numerous studies indicating that a violation of NMDA-receptor transmission contributes to the clinical manifestation of motor and nonmotor symptoms of Parkinson's disease and dyskinesia caused by taking L-DOPA drugs (Mellone and Gardoni 2018). It has been shown that, in addition to the main agonist of L-glutamate, such amino acids as D-aspartate and D-serine also play a role in NMDA receptor transmission in neurodegenerative diseases, a decrease in the level of which in the substantia nigra was associated with dopaminergic denervation, and a reduced concentration in spinal fluid - with clinical manifestations of Parkinson's disease in patients without substitution therapy with L-DOPA drugs (Wolosker et al. 2016; Nuzzo et al. 2019).

The severity of catalepsy with the injection of IEM-2295 decreased on average to 3 points, while in the control group it remained at the level of 6 points throughout the observation. However, the severity of catalepsy with the introduction of IEM-2296 decreased to an average of 4 points, but the effect itself lasted longer than with the introduction of IEM-2295. Thus, it was noted that by the 120th minute of observation, the severity of catalepsy in rats receiving the IEM-2295 compound averaged 5 points, whereas in animals receiving IEM-2296 – 3 points.

Basing on the results of our work and similar experiments, we can conclude that the studied compounds, which are not channel blockers, have an active effect on dopaminergic neurotransmission, because of which the symptoms of catalepsy that occur when haloperidol is injected to rats were stopped to one degree or another.

Possible steps in future research will be the study of the selectivity of the interaction of the studied compounds, as well as experimental work on other models of Parkinsonism in order to expand the understanding of the therapeutic possibilities of the studied compounds (Ugale et al. 2021; Vecchia et al. 2021). Thus, we will be one step closer to creating safe and cost-effective medicines in the near future.

Conclusion

It can be concluded based on the obtained results that the studied substances exhibit antiparkinsonian activity on an experimental haloperidol model of catalepsy in rats and are promising for development as potential therapies for neurodegenerative diseases. Considering the proposed mechanism of action of the studied substances, ligands of the glutamate NMDA receptor complex - 1,2-substituted imidazole-4,5-dicarboxylic acids, which is based on non-channel-blocking antagonism of NMDAR, one can hope for the possibility of safer therapy of Parkinsonism compared to the existing medicinal substances. The studied doses of compounds showed an interesting result, especially doses of 30 mg/kg for IEM-2295 and 20 mg/kg for IEM-2296. Further study of these compounds and other ligands from the NMDA-blocker group in a wider sample on the catalepsy model, in higher dosages, as well as on other models of Parkinsonism, is required.

Conflict of interests

The authors declare no conflict of interests.

References

- Aradi SD, Hauser RA (2020) Medical management and prevention of motor complications in Parkinson's disease. Neurotherapeutics 17(4): 1339–1365. https://doi.org/10.1007/s13311-020-00889-4 [PubMed] [PMC]
- Bhattacharya S, Ma Y, Dunn AR, Bradner JM, Scimemi A, Miller GW, Traynelis SF, Wichmann T (2018) NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate. Journal of Neuroscience Research 96(7): 1324–1335. https://doi.org/10.1002/jnr.24230 [PubMed] [PMC]
- Cárcel L, De la Casa LG (2021) Temporal factors modulate haloperidol-induced conditioned catalepsy. Frontiers in Behavioral Neuroscience 15: 713512. https://doi.org/10.3389/fnbeh.2021.713512 [PubMed] [PMC]
- Chia SJ, Tan E-K, Chao Y-X (2020) Historical perspective: Models of Parkinson's disease. International Journal of Molecular

Sciences 21(7): 2464. https://doi.org/10.3390/ijms21072464 [PubMed] [PMC]

- Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F (2018) The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? Parkinsonism & Related Disorders 51: 9–16. https://doi.org/10.1016/j.parkreldis.2018.02.001 [PubMed]
- Christoffersen CL, Meltzer LT (1995) Evidence for N-methyl-daspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: Possible preferential role for N-methyl-d-aspartate receptors. Neuroscience 67(2): 373–381. https://doi.org/10.1016/0306-4522(95)00047-M [PubMed]
- Cieślik P, Woźniak M, Tokarski K, Kusek M, Pilc A, Płoska A, Radulska A, Pelikant-Małecka I, Żołnowska B, Sławiński J, Kalinowski L, Wierońska JM (2019) Simultaneous activation of muscarinic and GABAB receptors as a bidirectional target for

novel antipsychotics. Behavioural Brain Research 359: 671–685. https://doi.org/10.1016/j.bbr.2018.09.019 [PubMed]

- Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents – preclinical studies. Neuroscience & Biobehavioral Reviews 21(4): 455–468. https://doi.org/10.1016/S0149-7634(96)00037-1 [PubMed]
- Dergachev VD, Yakovleva EE, Brusina MA, Bychkov ER, Piotrovskiy LB, Shabanov PD (2021) Antiparkinsonian activity of new N-methyl-D-aspartate receptor ligands in the arecoline hyperkinesis test. Medical Council [Meditsinskiy Sovet] 12: 406– 412. https://doi.org/10.21518/2079-701X-2021-12-406-412
- Draoui A, El Hiba O, Aimrane A, El Khiat A, Gamrani H (2020) Parkinson's disease: From bench to bedside. Revue Neurologique 176(7-8): 543–559. https://doi.org/10.1016/j.neurol.2019.11.002 [PubMed]
- Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S; COPARK Study Group (2020) Utilization patterns of amantadine in parkinson's disease patients enrolled in the french COPARK study. Drugs & Aging 37(3): 215–223. https://doi.org/10.1007/s40266-019-00740-2 [PubMed]
- Fox SH, Katzenschlager R, Lim S-Y, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, on behalf of the Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidencebased medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders 33(8): 1248–1266. https://doi.org/10.1002/mds.27372 [PubMed]
- Groc L, Choquet D (2020) Linking glutamate receptor movements and synapse function. Science 368(6496): eaay4631. https://doi.org/10.1126/science.aay4631 [PubMed]
- Haas KT, Compans B, Letellier M, Bartol TM, Grillo-Bosch D, Sejnowski TJ, Sainlos M, Choquet D, Thoumine O, Hosy E (2018) Pre-post synaptic alignment through neuroligin-1 tunes synaptic transmission efficiency. eLife 7: e31755. https://doi.org/10.7554/eLife.31755 [PubMed] [PMC]
- Iakovleva EE, Brusina MA, Bychkov ER, Piotrovsky LB, Shabanov PD (2020) Antiparkinsonian activity of new ligands of the glutamate NMDA-receptor complex – imidazole-4,5dicarboxylic acid derivatives. Bulletin of the Smolensk State Medical Academy [Vestnik Smolenskoi Gosudarstvennoi Meditsinskoi Akademii] 19: 41–47. https://doi.org/10.37903/vsgma.2020.3.5 [in Russian]
- Jankovic J, Tan EK (2020) Parkinson's disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry 91(8): 795–808. https://doi.org/10.1136/jnnp-2019-322338 [PubMed]
- Kabra A, Baghel US, Hano C, Martins N, Khalid M, Sharma R (2020) Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson's disease. Journal of Ayurveda and Integrative Medicine 11(4): 448–454. https://doi.org/10.1016/j.jaim.2020.06.007 [PubMed] [PMC]
- Kulisevsky J, Oliveira L, Fox SH (2018) Update in therapeutic strategies for Parkinson's disease. Current Opinion in Neurology 31(4): 439–447. https://doi.org/10.1097/WCO.000000000000579 [PubMed]
- Li B-D, Bi Z-Y, Liu J-F, Si W-J, Shi Q-Q, Xue L-P, Bai J (2017) Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison. CNS Neuroscience & Therapeutics 23(10): 827–842. https://doi.org/10.1111/cns.12727 [PubMed] [PMC]
- Mellone M, Gardoni F (2018) Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications. Journal of Neural Transmission 125(8): 1225–1236. https://doi.org/10.1007/s00702-018-1846-8 [PubMed]
- Mironov AN, Bunjatjan ND, Vasil'ev AN, Verstakova OL, Zhuravleva MV, Lepakhin VK (2012) Vol. 1 Guidelines for conducting preclinical research of medicines. Moscow: Grif and K, 944 pp. [in Russian]
- Mironova YuS, Zhukova NG, Zhukova IA, Alifirova VM, Izhboldina OP, Latypova AV (2018) Parkinson's disease and glutamatergic system. Korsakov Journal of Neurology and

Psychiatry [Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova] 118: 138. https://doi.org/10.17116/jnevro201811851138 [in Russian]

- Müller T, Kuhn W, Möhr J-D (2019) Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia. Expert Opinion on Pharmacotherapy 20(10): 1181–1187. https://doi.org/10.1080/14656566.2019.1612365 [PubMed]
- Nuzzo T, Punzo D, Devoto P, Rosini E, Paciotti S, Sacchi S, Li Q, Thiolat M-L, Véga C, Carella M, Carta M, Gardoni F, Calabresi P, Pollegioni L, Bezard E, Parnetti L, Errico F, Usiello A (2019) The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. Scientific Reports 9(1): 8898. https://doi.org/10.1038/s41598-019-45419-1 [PubMed] [PMC]
- Perez-Lloret S, Rascol O (2018) Efficacy and safety of amantadine for the treatment of 1-DOPA-induced dyskinesia. Journal of Neural Transmission 125(8): 1237–1250. https://doi.org/10.1007/s00702-018-1869-1 [PubMed]
- Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson's disease. Nature Reviews Disease Primers 3: 17013. https://doi.org/10.1038/nrdp.2017.13 [PubMed]
- Ramírez-Jarquín UN, Shahani N, Pryor W, Usiello A, Subramaniam S (2020) The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior. Translational Psychiatry 10(1): 336. https://doi.org/10.1038/s41398-020-011014-x [PubMed] [PMC]
- Schwab RS (1969) Amantadine in the treatment of Parkinson's disease. JAMA: The Journal of the American Medical Association 208(7): 1168. https://doi.org/10.1001/jama.1969.03160070046011 [PubMed]
- Standaert DG, Testa CM, Young AB, Penney JB (1994) Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. The Journal of Comparative Neurology 343(1): 1–16. https://doi.org/10.1002/cne.903430102 [PubMed]
- Szydlowska K, Tymianski M (2010) Calcium, ischemia and excitotoxicity. Cell Calcium 47(2): 122–129. https://doi.org/10.1016/j.ceca.2010.01.003 [PubMed]
- Tarakad A (2020) Clinical rating scales and quantitative assessments of movement disorders. Neurologic Clinics 38(2): 231–254. https://doi.org/10.1016/j.ncl.2019.12.001 [PubMed]
- Ugale V, Dhote A, Narwade R, Khadse S, Reddy PN, Shirkhedkar A (2021) GluN2B/N-methyl-D-aspartate receptor antagonists: advances in design, synthesis, and pharmacological evaluation studies. CNS & Neurological Disorders – Drug Targets 20(9): 822–862. https://doi.org/10.2174/1871527320666210309141627 [PubMed]
- Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW (2018) NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. Translational Psychiatry 8(1): 117. https://doi.org/10.1038/s41398-018-0162-2 [PubMed] [PMC]
- Vecchia DD, Kanazawa LKS, Wendler E, Hocayen P de AS, Vital MABF, Takahashi RN, Da Cunha C, Miyoshi E, Andreatini R (2021) Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease. Brain Research Bulletin 168: 63–73. https://doi.org/10.1016/j.brainresbull.2020.12.011 [PubMed]
- Vieira M, Yong XLH, Roche KW, Anggono V (2020) Regulation of NMDA glutamate receptor functions by the GluN2 subunits. Journal of Neurochemistry 154(2): 121–143. https://doi.org/10.1111/jnc.14970 [PubMed] [PMC]
- Wang R, Reddy PH (2017) Role of glutamate and NMDA receptors in Alzheimer's disease. Journal of Alzheimer's Disease 57(4): 1041–1048. https://doi.org/10.3233/JAD-160763 [PubMed] [PMC]
- Wolosker H, Balu DT, Coyle JT (2016) The rise and fall of the dserine-mediated gliotransmission hypothesis. Trends in Neurosciences 39(11): 712–721. https://doi.org/10.1016/j.tins.2016.09.007 [PubMed] [PMC]

Author contributions

- Vladimir D. Dergachev, post-graduate student, S.V. Anichkov Department of Neuropharmacology, e-mail: archegurrez@yandex.com, ORCID ID https://orcid.org/0000-0002-3098-1060. The author was engaged in planning and conducting the experiment, statistical processing and analysis of the results, discussions, and conclusions, as well as in manuscript design; work with graphic material; editing and processing the manuscript.
- Ekaterina E. Yakovleva, PhD in Medicine, Researcher at the Laboratory of Chemistry and Pharmacology of Pharmaceutical Drugs, S.V. Anichkov Department of Neuropharmacology, Institute of Experimental Medicine; Assistant, Department of Pharmacology, St. Petersburg Pediatric Medical University, e-mail: eeiakovleva@mail.ru, ORCID ID https://orcid.org/0000-0002-0270-0217. The author was engaged in planning and conducting the experiment, statistical processing and analysis of the results, discussions, and conclusions.
- Maria A. Brusina, PhD in Chemistry, Junior Researcher at The Laboratory for Synthesis and Nanotechnology of Drugs, S.V. Anichkov Department of Neuropharmacology, e-mail: mashasemen@gmail.com, ORCID ID https://orcid.org/0000-0001-8433-120X. The author was engaged in planning of the experiment and the synthesis of the studied compounds.
- Evgeny R. Bychkov, PhD in Medicine, Head of the Laboratory of Chemistry and Pharmacology of Pharmaceutical Drugs, S.V. Anichkov Department of Neuropharmacology, e-mail: bychkov@mail.ru, ORCID ID https://orcid.org/0000-0003-1068-4701. The author was engaged in planning and development of research design, as well as in comparative analysis.
- Levon B. Piotrovskiy, PhD in Biology, Head of The Laboratory for Synthesis and Nanotechnology of Drugs, S.V. Anichkov Department of Neuropharmacology, e-mail: levon-piotrovsky@yandex.ru, ORCID ID https://orcid.org/0000-0001-8679-1365. The author was engaged in planning and development of research design, control over the synthesis of the necessary compounds, as well as in collection, analysis and generalization of literature data, collection and systematization of data.
- Petr D. Shabanov, PhD in Medicine, Professor, Head of the S.V. Anichkov Department of Neuropharmacology, e-mail: pdshabanov@mail.ru, ORCID ID https://orcid.org/0000-0003-1464-1127. The author was engaged in planning and development of research design, analysis and systematization of experimental data.